1. Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
- Author
-
Salihovic, Samira, Nyström, Niklas, Mathisen, Charlotte Bache-Wiig, Kruse, Robert, Olbjorn, Christine, Andersen, Svend, Noble, Alexandra J., Dorn-Rasmussen, Maria, Bazov, Igor, Perminow, Gori, Opheim, Randi, Detlie, Trond Espen, Huppertz-Hauss, Gert, Hedin, Charlotte R. H., Carlson, Marie, Ohman, Lena, Magnusson, Maria K., Keita, Asa V., Soderholm, Johan D., D'Amato, Mauro, Oresic, Matej, Wewer, Vibeke, Satsangi, Jack, Lindqvist, Carl Marten, Burisch, Johan, Uhlig, Holm H., Repsilber, Dirk, Hyotylainen, Tuulia, Hoivik, Marte Lie, Halfvarson, Jonas, Salihovic, Samira, Nyström, Niklas, Mathisen, Charlotte Bache-Wiig, Kruse, Robert, Olbjorn, Christine, Andersen, Svend, Noble, Alexandra J., Dorn-Rasmussen, Maria, Bazov, Igor, Perminow, Gori, Opheim, Randi, Detlie, Trond Espen, Huppertz-Hauss, Gert, Hedin, Charlotte R. H., Carlson, Marie, Ohman, Lena, Magnusson, Maria K., Keita, Asa V., Soderholm, Johan D., D'Amato, Mauro, Oresic, Matej, Wewer, Vibeke, Satsangi, Jack, Lindqvist, Carl Marten, Burisch, Johan, Uhlig, Holm H., Repsilber, Dirk, Hyotylainen, Tuulia, Hoivik, Marte Lie, and Halfvarson, Jonas
- Abstract
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-na & iuml;ve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making. Diagnostic blood-based biomarkers of pediatric IBD are limited. Here, the authors demonstrate a diagnostic lipidomic signature, comprising only of two molecular lipids. Translation of this signature into a scalable test has the potential to support clinical decision making.
- Published
- 2024
- Full Text
- View/download PDF